Mediolanum International Funds Ltd Buys 5,290 Shares of argenx SE (NASDAQ:ARGX)

Mediolanum International Funds Ltd boosted its stake in argenx SE (NASDAQ:ARGX - Free Report) by 49.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,984 shares of the company's stock after acquiring an additional 5,290 shares during the quarter. Mediolanum International Funds Ltd's holdings in argenx were worth $8,550,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. TD Asset Management Inc boosted its holdings in argenx by 15.4% in the first quarter. TD Asset Management Inc now owns 223,695 shares of the company's stock valued at $88,073,000 after purchasing an additional 29,810 shares during the last quarter. Seven Eight Capital LP boosted its position in argenx by 66.4% during the 1st quarter. Seven Eight Capital LP now owns 3,110 shares of the company's stock valued at $1,224,000 after purchasing an additional 1,241 shares during the period. Clearbridge Investments LLC grew its stake in argenx by 36.5% during the 1st quarter. Clearbridge Investments LLC now owns 596,277 shares of the company's stock worth $234,766,000 after buying an additional 159,480 shares during the last quarter. FORA Capital LLC acquired a new stake in argenx in the first quarter worth $2,024,000. Finally, Fiera Capital Corp increased its position in argenx by 2.2% in the second quarter. Fiera Capital Corp now owns 165,595 shares of the company's stock worth $71,212,000 after buying an additional 3,506 shares during the period. Institutional investors and hedge funds own 60.32% of the company's stock.

Wall Street Analyst Weigh In

ARGX has been the subject of several recent research reports. Evercore ISI upped their price target on shares of argenx from $478.00 to $533.00 and gave the stock an "outperform" rating in a research report on Friday, July 12th. Deutsche Bank Aktiengesellschaft lowered argenx from a "buy" rating to a "hold" rating in a report on Friday, October 4th. JPMorgan Chase & Co. lifted their target price on argenx from $500.00 to $640.00 and gave the company an "overweight" rating in a research note on Friday, August 23rd. Oppenheimer raised shares of argenx from a "market perform" rating to an "outperform" rating and set a $546.00 target price on the stock in a research note on Tuesday, July 23rd. Finally, Truist Financial upped their price target on shares of argenx from $480.00 to $540.00 and gave the stock a "buy" rating in a research note on Monday, July 22nd. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $550.44.

argenx Trading Up 1.0 %

Shares of argenx stock traded up $5.68 during trading on Friday, reaching $556.83. The company's stock had a trading volume of 135,027 shares, compared to its average volume of 307,768. argenx SE has a one year low of $327.73 and a one year high of $571.97. The stock has a 50-day moving average price of $534.84 and a two-hundred day moving average price of $459.81. The stock has a market capitalization of $33.09 billion, a P/E ratio of -98.38 and a beta of 0.63.

argenx (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $1.34. argenx had a negative return on equity of 7.33% and a negative net margin of 12.31%. The firm had revenue of $489.43 million for the quarter, compared to the consensus estimate of $436.66 million. During the same quarter in the prior year, the business earned ($1.69) EPS. As a group, sell-side analysts anticipate that argenx SE will post -0.37 EPS for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.